PFE

Pfizer Inc.

HealthcareDrug Manufacturers - GeneralNASDAQ

$27.32

+$0 (0.00%)today

Conviction

0/ 10

Fair Value$28.58

Upside+4.61%

Signal0

Market Cap$158.0B

52W Range$20.92–$27.94

Next EarningsMay 5

Price History

FAIR VALUE ANALYSISMonte Carlo · 5,000 runs · 99% valid

Fair Value$53.82

Current Price$26.97

Upside / Down+99.6%

P(Undervalued)100.0%

P(20%+ Up)99.6%

P(15%+ Down)0.0%

Fair Value Distribution — percentile bands

100.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

-8.3%/yr

±1.7% · revenue growth to justify current price

FCF-Based Reverse DCF

-2.0%/yr

±3.1% · FCF growth to justify current price

THE GAP

Market pricing margin compression or rising capex

KEY VALUE DRIVERS

Spearman correlation — what moves this valuation most

Quick Take

Pfizer Inc.

Trailing P/E20.4x

Forward P/E9.8x

P/S2.5x

EPS (TTM)$1.36

Analyst Target$28.58

Analyst Upside4.6%

No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.

Bull Case

No analysis yet

Bear Case

No analysis yet

Research Feed

sec_10kFeb 28

Conviction: unchanged

Pfizer FY2025 10-K: Patent Cliff Looms, Seagen ADC Bet, Obesity Optionality

PFE FY2025: ~.2B revenue (down ~2.5% from ~.8B in 2024). International .5B = 41% of total. COVID product normalization masks ex-COVID stability. Massive patent cliff ahead: Eliquis (2028), Ibrance (20...